Z
Zhenshun Cheng
Researcher at Wuhan University
Publications - 13
Citations - 36620
Zhenshun Cheng is an academic researcher from Wuhan University. The author has contributed to research in topics: Medicine & Internal medicine. The author has an hindex of 1, co-authored 1 publications receiving 26390 citations.
Papers
More filters
Journal ArticleDOI
Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China
Chaolin Huang,Yeming Wang,Xingwang Li,Lili Ren,Jianping Zhao,Yi Hu,Li Zhang,Guohui Fan,Jiuyang Xu,Xiaoying Gu,Zhenshun Cheng,Ting Yu,Jia'an Xia,Yuan Wei,Wenjuan Wu,Xuelei Xie,Wen Yin,Li Hui,Min Liu,Yan Xiao,Hong Gao,Li Guo,Jungang Xie,Guang-Fa Wang,Rongmeng Jiang,Zhancheng Gao,Qi Jin,Jianwei Wang,Bin Cao +28 more
TL;DR: The epidemiological, clinical, laboratory, and radiological characteristics and treatment and clinical outcomes of patients with laboratory-confirmed 2019-nCoV infection in Wuhan, China, were reported.
Journal ArticleDOI
High-flow nasal cannula versus conventional oxygen therapy in acute COPD exacerbation with mild hypercapnia: a multicenter randomized controlled trial
Jingen Xia,Sichao Gu,Wei Lei,Jihua Zhang,Huijing Wei,Chao Liu,Han Zhang,Rong-li Lu,Liqiong Zhang,Mingyan Jiang,Chao Hu,Zhenshun Cheng,Chaojie Wei,Yusheng Chen,Feng Lu,Min Chen,Honghao Bi,Hui Liu,C. Yan,Hong Teng,Yang Yang,Chen Liang,Yanlei Ge,Pengguo Hou,Jialin Liu,Weiwei Gao,Yi Zhang,Yingying Feng,Cheng Tao,Xu Huang,Pinhua Pan,Hong Luo,Chunmei Yun,Qingyuan Zhan +33 more
TL;DR: In this paper , a randomized controlled trial was conducted from July 2017 to December 2020 in 16 tertiary hospitals in China, where patients with acute COPD exacerbation with mild hypercapnia (pH ≥ 7.35 and arterial partial pressure of carbon dioxide > 45 mmHg) were randomly assigned to either HFNC or conventional oxygen therapy.
Journal ArticleDOI
Polymyxin B/Tigecycline Combination vs. Polymyxin B or Tigecycline Alone for the Treatment of Hospital-Acquired Pneumonia Caused by Carbapenem-Resistant Enterobacteriaceae or Carbapenem-Resistant Acinetobacter baumannii
Kang Han Chang,Haibo Wang,Jianping Zhao,Xianghong Yang,Bo Wu,Wenkui Sun,Man Huang,Zhenshun Cheng,Hong Chen,Yuanlin Song,Ping Chen,Xiangqian Chen,Xin Gan,Wanli Ma,Lihua Xing,Limin Wang,Xiaoying Gu,Xiaohui Zou,Bin Cao +18 more
TL;DR: The appropriate PMB/TGC combination was not superior toappropriate PMB therapy in the treatment of HAP caused by carbapenem-resistant Enterobacteriaceae/carbapenems-resistant Acinetobacter baumannii (CRE/CRAB) in terms of 28-day mortality.
Journal ArticleDOI
Risk factors for polymyxin B-associated acute kidney injury.
Kang Han Chang,Haibo Wang,Jianping Zhao,Xianghong Yang,B.H. Wu,Wenkui Sun,Man Huang,Zhenshun Cheng,Hong Chen,Yuanlin Song,Ping Chen,Xiangqian Chen,Xin Gan,Wanli Ma,Lihua Xing,Limin Wang,B. Cao +16 more
TL;DR: In this article , a multicenter, retrospective cohort study included patients from 14 Chinese teaching hospitals who received polymyxin B therapy. And a multivariate logistic regression model was used to identify independent risk factors for AKI.
Journal ArticleDOI
Dec1 Deficiency Ameliorates Pulmonary Fibrosis Through the PI3K/AKT/GSK-3β/β-Catenin Integrated Signaling Pathway
TL;DR: Findings indicated that during PF progression, DEC1 played a key role in EMT via the PI3K/AKT/GSK-3β/β-catenin integrated signaling pathway and targeting DEC1 may be a potential novel therapeutic approach for IPF.